Home » Stocks » TRVI

Trevi Therapeutics, Inc. (TRVI)

Stock Price: $1.95 USD -0.03 (-1.52%)
Updated Aug 3, 2021 12:25 PM EDT - Market open
Market Cap 40.98M
Revenue (ttm) n/a
Net Income (ttm) -32.66M
Shares Out 21.57M
EPS (ttm) -1.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $1.95
Previous Close $1.98
Change ($) -0.03
Change (%) -1.52%
Day's Open 1.98
Day's Range 1.90 - 1.99
Day's Volume 7,263
52-Week Range 1.78 - 8.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW HAVEN, Conn., June 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational...

1 month ago - PRNewsWire

NEW HAVEN, Conn., May 13, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational...

2 months ago - PRNewsWire

NEW HAVEN, Conn., May 6, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational t...

2 months ago - PRNewsWire

NEW HAVEN, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nal...

3 months ago - GlobeNewsWire

Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021

4 months ago - GlobeNewsWire

Conference Call and Webcast to be Held at 4:30 p.m. ET Conference Call and Webcast to be Held at 4:30 p.m. ET

4 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor in Trevi Therapeutics (TRVI).

6 months ago - Zacks Investment Research

Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications

6 months ago - GlobeNewsWire

Trevi Therapeutics' (TRVI) CEO Jennifer Good on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

PRISM Trial of Haduvio ™ for Severe Pruritus in Patients with Prurigo Nodularis 

8 months ago - GlobeNewsWire

NEW HAVEN, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalb...

8 months ago - GlobeNewsWire

Conference Call and Webcast to be Held at 4:30 p.m. ET Conference Call and Webcast to be Held at 4:30 p.m. ET

8 months ago - GlobeNewsWire

Expands Management Team to Support Clinical Development and Commercial Strategy of Haduvio™ in Multiple Late Stage Programs Expands Management Team to Support Clinical Development and Commercial Strateg...

9 months ago - GlobeNewsWire

NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (n...

10 months ago - GlobeNewsWire

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Announced Positive Outcome of Sample Size Re-Estimation Analysis for PRISM Trial

11 months ago - GlobeNewsWire

NEW HAVEN, Conn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (na...

11 months ago - GlobeNewsWire

Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design

1 year ago - GlobeNewsWire

Seasoned biopharmaceutical executive with over 20 years of executive leadership and corporate development experience Seasoned biopharmaceutical executive with over 20 years of executive leadership and c...

1 year ago - GlobeNewsWire

NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine E...

1 year ago - GlobeNewsWire

Analysts on Wall Street recommend buying shares of Trevi Therapeutics Inc (NASDAQ:TRVI) and Carter Bank & Trust (NASDAQ:CARE), even though their share prices have lost more than 59% over the past 52 wee...

Other stocks mentioned: CARE
1 year ago - GuruFocus

Seasoned biopharmaceutical executive with over 30 years of drug development experience Seasoned biopharmaceutical executive with over 30 years of drug development experience

1 year ago - GlobeNewsWire

Trevi Therapeutics: A Promising Pruritus Player In 2020

1 year ago - Seeking Alpha

Trevi Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ...

1 year ago - GlobeNewsWire

Trevi Therapeutics Inc (NASDAQ: TRVI) priced its 5.5 million share IPO at $10 May 7, and shares have been mostly trading at a discount since then.

2 years ago - Benzinga

About TRVI

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated... [Read more...]

Industry
Biotechnology
IPO Date
May 7, 2019
Stock Exchange
NASDAQ
Ticker Symbol
TRVI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price forecast is 11.33, which is an increase of 481.03% from the latest price.

Price Target
$11.33
(481.03% upside)
Analyst Consensus: Strong Buy